Oldrich Chrapek Selected Research

Photochemotherapy (Photodynamic Therapy)

1/2014

Progression of macular atrophy after PDT combined with the COX-2 inhibitor Nabumetone in the treatment of neovascular ARMD.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Oldrich Chrapek Research Topics

Disease

2	Macular Degeneration (Age-Related Maculopathy) 09/2015 - 01/2014
1	Diabetic Retinopathy (Retinopathy, Diabetic) 12/2023
1	Choroidal Neovascularization 09/2015
1	Central Serous Chorioretinopathy 03/2015
1	Retinal Detachment (Retinal Detachments) 01/2015
1	Macular Edema 01/2015
1	Atrophy 01/2014
1	Endophthalmitis (Ophthalmia) 03/2012
1	Ischemia 01/2011

Drug/Important Bio-Agent (IBA)

2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2015 - 01/2015
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2023
1	Ranibizumab (Lucentis)FDA Link 09/2015
1	Metipranolol FDA LinkGeneric 03/2015
1	Retinaldehyde (Retinal)IBA 01/2015
1	Uric Acid (Urate)IBA 01/2015
1	Nabumetone FDA LinkGeneric 01/2014
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2014
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2014
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2014
1	oxane HDIBA 03/2012
1	Silicone OilsIBA 03/2012
1	densironIBA 03/2012

Therapy/Procedure

1	Photochemotherapy (Photodynamic Therapy) 01/2014
1	Vitrectomy 03/2012
1	Light Coagulation 01/2011